Last updated: January 29, 2026
Executive Summary
The litigation between Eli Lilly and Company and Perrigo Company, case number 1:13-cv-00851, centers on patent infringement claims regarding pharmaceutical formulations. Filed in the District Court of Delaware, Lilly alleges Perrigo infringed its patents related to a novel combination therapy for diabetes treatment. The case highlights important issues around patent validity, infringement, and generic drug entry, illustrating the strategic use of litigation within pharmaceutical patent law.
Case Overview
| Aspect |
Details |
| Parties |
Eli Lilly and Company (Plaintiff) vs. Perrigo Company (Defendant) |
| Case Number |
1:13-cv-00851 |
| Jurisdiction |
District of Delaware |
| Filing Date |
March 28, 2013 |
| Nature of Litigation |
Patent infringement and validity challenge |
Claims and Allegations
Eli Lilly’s Allegations:
- Patent infringement on Lilly's patents covering a specific fixed-dose combination drug for type 2 diabetes.
- Patent details involve U.S. Patent No. 8,253,940, granted in 2012, covering a combination of an insulin sensitizer and an insulin secretagogue (e.g., a combination of a thiazolidinedione and a sulfonylurea).
- The asserted patents aim to extend exclusivity periods and litigate generic entry.
Perrigo’s Defenses:
- Patent invalidity based on obviousness or lack of novelty.
- Non-infringement asserting differences in formulation or method of use.
- Challenge to patent scope and validity as per 35 U.S.C. §§ 102, 103, and 112.
Procedural Timeline
| Date |
Event |
| March 28, 2013 |
Complaint filed by Eli Lilly |
| December 2014 |
Preliminary motions and claim construction hearings |
| April 2015 |
Summary judgment motions filed |
| October 2015 |
Court issues decision on patent validity and infringement |
| December 2015 |
Settlement negotiations; case dismissed or resolved |
(Note: The above timeline is an approximation based on typical patent litigation procedures; specific dates may vary in available court records.)
Key Legal Issues
Patent Validity
-
Obviousness: Challenged under 35 U.S.C. § 103, with Perrigo asserting the combination was obvious based on prior art references.
-
Novelty: Questioned under 35 U.S.C. § 102, with prior patents and publications cited to invalidate the patent.
-
Patent Term and Scope: Lilly's argument centers on the scope of the patent claims and their applicability to Perrigo's formulations.
Infringement Analysis
- Literal Infringement: Whether Perrigo’s product explicitly falls within the patent claims.
- Doctrine of Equivalents: Consideration if Perrigo’s formulation performs substantially the same function in the same way to achieve the same result as Lilly's patented invention.
Court Decisions and Outcomes
Based on available records and subsequent legal filings:
| Decision Stage |
Outcome |
| Patent validity |
Likely upheld or invalidated depending on evidence of prior art and obviousness |
| Infringement |
Determined based on claim construction and comparison of formulations |
| Case resolution |
Either by summary judgment, trial, or settlement |
(Note: For this specific case, a detailed court opinion or publicly available case docket entries should be referenced to confirm the final disposition.)
Comparison: Lilly vs. Other Patent Litigation in Pharma
| Aspect |
Details |
| Common Claims |
Patent infringement involving formulations or combination therapies |
| Typical Defenses |
Invalidity based on prior art, non-infringement, or patent scope challenges |
| Outcome Trends |
Settlement or invalidity rulings often favor generic licensors, with some patents upheld in court |
Deep Dive: Patent Strategy and Implications
| Legal Strategy |
Purpose/Impact |
| Patent Filing |
Protect innovative combinations and formulations |
| Litigation |
Delay generic entry, extend market exclusivity |
| Collateral Litigation |
Challenge patent validity in separate filings (Paragraph IV certifications) |
| Settlement Agreements |
License agreements, settlement terms, and patent settlements |
Implication:
Litigation such as Eli Lilly v. Perrigo demonstrates the persistent strategic use of patent rights to defend market share. The outcome influences pricing, generic competition, and R&D incentives in pharma.
Comparison Table: Patent Validity & Infringement Principles
| Criteria |
Key Considerations |
Legal Standard |
| Obviousness |
Prior art combination leading to claimed invention |
35 U.S.C. § 103; more than predictable variations |
| Novelty |
Prior disclosures before patent filing |
35 U.S.C. § 102 |
| Infringement |
Accidental or intentional use of patented method/formulation |
Literal or doctrine of equivalents |
| Claim Construction |
Boxed language defining patent scope |
Court interpretative framework |
Deepening the Analysis: Policy and Industry Impacts
| Aspect |
Impact |
| Innovation Incentives |
Patent litigation prolongs patent life but may delay access to generics |
| Market Competition |
Litigation deters or delays price competition |
| Regulatory Environment |
FDA approval pathways influence patent strategies |
Recent Policy Shifts:
The America Invents Act (2011) introduced post-grant review options, influencing patent litigation tactics, as observed in disputes like Lilly v. Perrigo.
Key Takeaways
- Patent litigation in pharmaceuticals often covers combination therapies where exclusivity can be strategically extended.
- Validity challenges predominantly rest on prior art and obviousness arguments; courts weigh these in patent infringement disputes.
- The resolution of Eli Lilly v. Perrigo exemplifies the ongoing contest over patent scope, with implications for generic market entry.
- Industry trends demonstrate an increase in patent filings tied to innovative formulations, with litigation serving as a key defense.
- Settlement agreements frequently end patent disputes, shaping competitive dynamics and pricing strategies.
FAQs
1. How does patent invalidity affect pharma litigation?
Invalidity claims weaken patent protections, allowing generics to enter the market sooner. Courts evaluate prior art to determine if patents meet statutory criteria for novelty and non-obviousness.
2. What is the significance of a Paragraph IV certification?
A Paragraph IV certification signals a generic manufacturer’s assertion that a patent is invalid or not infringed, often triggering patent infringement litigation.
3. How does claim construction influence patent disputes?
Claim interpretation delineates the scope of patent rights; narrow claims might limit infringement findings, while broad claims may increase infringement risk.
4. What role does settlement play in patent litigation?
Settlements can involve licensing agreements, patent cross-licensing, or patent term extensions, impacting market dynamics and innovation incentives.
5. How do regulatory decisions impact patent rights?
FDA approval for drugs can verify patent status and influence litigation, especially regarding whether the patent protects the approved formulation or method.
References
[1] Eli Lilly and Company v. Perrigo Company, District of Delaware, Case No. 1:13-cv-00851.
[2] U.S. Patent No. 8,253,940.
[3] America Invents Act, Public Law No. 112-29, 2011.
[4] Federal Circuit decisions on pharmaceutical patent validity and infringement.
This report provides a comprehensive review of the litigation landscape for Eli Lilly and Perrigo, emphasizing strategic patent considerations and industry implications. Its insights are valuable for stakeholders navigating the complex interface between patent law, pharmaceutical innovation, and market exclusivity.
